Study populations

The Northern Finland Birth Cohorts (NFBC) of 1986 and 1966 were initiated to study factors affecting preterm birth and subsequent morbidity in the two northernmost provinces in Finland (www.oulu.fi/NFBC). For NFBC1986, the number of deliveries in the birth cohort was 9,362, which was 99% of all the deliveries taking place in the area during the target period (July 1985-June 1986). Data collection in 2001-2002 included clinical examination and serum sampling at age 15-16 for 6,621 adolescent boys and girls; data from this time point are used for the present study [1,2]. Attendees in the 16-year field study (71%) were representative of the original cohort [2]. In total, 5,602 adolescents had a systemic metabolite profile measured, of which 95% of the serum samples were drawn after overnight fasting. Among these individuals, 3,976 study participants had also information available on the gene score for predisposition to elevated BMI from genotyping using the CardioMetabochip.

The NFBC1966 included 12,058 children born into the cohort, comprising 96% of all births during 1966 in the region [3,4]. Data collection in 1997 included clinical examination and serum sampling at age 31 for 6,007 individuals. Data from this time point are analyzed in the present study. Attendees in the 31-year field study (52%) were representative of the original cohort [3]. In total, 5,709 persons had their metabolite profile measured, of which 96% were based on fasting serum samples [5]. Among these, n=4,671 individuals also had information available on the gene score for elevated BMI based on genome-wide arrays and were included in the present study.

For both NFBC studies, blood pressure was measured using a mercury sphygmomanometer. Physical activity index was calculated as metabolic-equivalent-of-task, based on questionnaire data on frequency, intensity, and duration of physical activity as described previously [1,5]. Current smoking and average alcohol usage were assessed from questionnaires (gram/day; NFBC1966 only). Medication for hypertension, diabetes and hypercholesterolemia was also determined by questionnaires. In addition to NMR-based metabolite quantification, plasma levels of the following protein biomarkers were measured by standard clinical assays and analyzed in the present study: C-reactive protein, alanine aminotransferase, gamma-glutamyl aminotransferase, direct bilirubin, and plasma insulin [5,6]. Testosterone and sex-hormone binding globulin were measured by mass spectrometry. Vitamin-D levels were measured for NFBC1966. Informed written consent was obtained from all participants, and the research protocols were approved by the Ethics Committee of Northern Ostrobotnia Hospital District, Finland.

The Cardiovascular Risk in Young Finns Study (YFS) was designed to study associations of childhood risk factors to cardiovascular disease in adulthood (youngfinnsstudy.utu.fi) [7]. The baseline study conducted in 1980 included 3,596 children and adolescents aged 3–18. Data in the cross-sectional analyses in the present study are predominantly from the 2001 survey, which included 2,247 individuals with an overnight fasting metabolite profile (response rate 63%). These individuals were
representative of the baseline cohort [7]. In addition, 288 individuals who only attended the
2007-survey were included in analyses. Genotype information on the gene score for elevated BMI
was available for n=2,171 participants based on genome-wide arrays. Longitudinal data on 6-year
change in BMI and change in metabolite levels were collected for 1,488 individuals, who
participated in both the 2001 and 2007 field studies and were free of medication for metabolic
diseases at both timepoints. The longitudinal associations were further assessed for consistency at
10-year follow-up (2001→2011; n=1,372).

Blood pressure was measured using a random-zero sphygmomanometer. Metabolic-
equivalent-of-task was used as physical activity index [5]. Current smoking, average alcohol usage
(gram/day) and medication for hypertension, diabetes and hypercholesterolemia were assessed
by questionnaires. In addition to NMR metabolite profiling, the following plasma biomarkers were
measured by standard clinical assays and analyzed in the present study: lipoprotein(a),
homocysteine, C-reactive protein, phospholipase A2 activity, alanine aminotransferase,
gamma-glutamyl aminotransferase, leptin, adiponectin, vitamin D, and insulin [5,7] Testosterone
and sex-hormone binding globulin were measured by mass spectrometry for both women and
men in 2001, but only for men in 2007. All participants gave written informed consent, and the
study was approved by the ethics committees of each of the five participating medical university
study sites in Finland.

The FINRISK 1997 study was conducted to monitor the health of the Finnish population among
persons aged 24–74 at recruitment (thl.fi/finriski) [8,9]. In total, 8,444 individuals were recruited to
represent the general population of the study areas. Blood pressure was measured and participants
filled in questionnaires of smoking status, alcohol usage, physical activity, and medication.9 In the
absence of sufficient information to derive metabolic-equivalent-of-task, a binary physical activity
index was defined based on the self-reported level of leisure time physical activity. Metabolite
profiling from serum samples were measured for 7,610 individuals, of which 5,804 were free of
prevalent cardiometabolic disease or treatment of lipid levels or hypertension. The median fasting
time was 5h (interquartile range 4–6h). Only individuals under the age of 40 were included the
primary analyses of the present study to minimize the influence of aging and reverse causality from
the comorbidities of obesity. Out of 2,128 participants in this age group, genotype information on
the gene score was available for n=1,846. The generalizability of the cross-sectional associations to
older age groups was examined separately for 3,676 individuals aged 40–74 (Figure 3). In addition
to NMR-based metabolite profiling, the following circulating biomarkers were assayed by standard
clinical assays and analyzed in the present study: lipoprotein(a), homocysteine, C-reactive protein,
phospholipase A2 activity, gamma-glutamyl aminotransferase, leptin, adiponectin, testosterone,
vitamin D, and insulin [9]. Participants gave written informed consent and the FINRISK study was
approved by the ethical committee of the National Public Health Institute, Helsinki, Finland.
The Piekämäki study
The generalizability of the cross-sectional and longitudinal results to older age groups was examined in the Piekämäki population cohort [10,11]. The Piekämäki cohort consisted of individuals from the town of Piekämäki, Eastern Finland, born in 1942, 1947, 1952, 1957 and 1962. There were 923 participants in the initial examination in 1997. In the present study, 628 individuals aged 40–57 with metabolite profile quantified and free of baseline medication were analyzed for the generalization of the cross-sectional results to older age groups (Figure 3). Of these, 456 persons had their metabolite profile measured again at a follow-up survey in 2003, which enabled generalization of the longitudinal results to older age (Figure S4). No genotype information was available. In addition to NMR-based metabolite profiling, the following metabolic measures were assayed in the Piekämäki study: C-reactive protein, adiponectin, insulin, and blood pressure. Participants gave written informed consent and the study protocol was approved by the Ethics Committee of Kuopio University Hospital.

Clinical definitions
Overweight was defined as BMI of 25–29.9 kg/m² and obesity as BMI≥30 kg/m².

References: